ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation.

PF, Laterre; E, Abraham; JM, Janes; BL, Trzaskoma; NL, Correll; FV, Booth

doi:10.1097/01.ccm.0000266588.95733.63

Public

ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation.

Shared by NobleBlocks on Jun 1, 2007 • 12:00 AM UTC

Authors:

Laterre PF

Abraham E

Janes JM

Abstract

Objective To demonstrate that drotrecogin alfa (activated) has an acceptable safety profile 1 yr from randomization.Design One-year follow-up of patients participating in a placebo-controlled clinical study of drotrecogin alfa (activated) in severe sepsis patients at low risk of death (the ADDRESS s...

Discussions